Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen

Appraisal Committee members

The Appraisal Committees are standing advisory committees of NICE. Members are appointed for a 3‑year term. A list of the Committee members who took part in the discussions for this appraisal appears below. There are 4 Appraisal Committees, each with a chair and vice chair. Each Appraisal Committee meets once a month, except in December when there are no meetings. Each Committee considers its own list of technologies, and ongoing topics are not moved between Committees.

Committee members are asked to declare any interests in the technology to be appraised. If it is considered there is a conflict of interest, the member is excluded from participating further in that appraisal.

The minutes of each Appraisal Committee meeting, which include the names of the members who attended and their declarations of interests, are posted on the NICE website.

Dr Amanda Adler (Chair)
Consultant Physician, Addenbrooke's Hospital

Professor Ken Stein (Vice Chair)
Professor of Public Health, Peninsula Technology Assessment Group (PenTAG), University of Exeter

Professor Keith Abrams
Professor of Medical Statistics, University of Leicester

Dr Jeff Aronson
Reader in Clinical Pharmacology, University Department of Primary Health Care, University of Oxford

Professor John Cairns
Professor of Health Economics Public Health and Policy, London School of Hygiene and Tropical Medicine

Mr Mark Chapman
Health Economics and Market Access Manager, Medtronic UK

Professor Fergus Gleeson
Consultant Radiologist, Churchill Hospital, Oxford

Mr Robert Hinchliffe
HEFCE Clinical Senior Lecturer in Vascular Surgery and Honorary Consultant Vascular Surgeon, St George's Vascular Institute

Dr Neil Iosson
Locum GP

Mrs Anne Joshua
Associate Director of Pharmacy, NHS Direct

Dr Rebecca Kearney
Clinical Lecturer, University of Warwick

Dr Miriam McCarthy
Consultant, Public Health, Public Health Agency

Professor Ruairidh Milne
Director of Strategy and Development and Director for Public Health Research at the National Institute for Health Research (NIHR) Evaluation, Trials and Studies Coordinating Centre, University of Southampton

Dr Elizabeth Murray
Reader in Primary Care, University College London

Mr Christopher O'Regan
Head of Health Technology Assessment and Outcomes Research, Merck Sharp & Dohme

Professor Stephen Palmer
Professor of Health Economics, Centre for Health Economics, University of York

Dr Sanjeev Patel
Consultant Physician and Senior Lecturer in Rheumatology, St Helier University Hospital

Dr Danielle Preedy
Lay Member

Dr John Rodriguez
Assistant Director of Public Health, NHS Eastern and Coastal Kent

Mr Alun Roebuck
Consultant Nurse in Critical and Acute Care, United Lincolnshire NHS Trust

Mr Cliff Snelling
Lay Member

Mr David Thomson
Lay member

Dr Nicky Welton
Senior Lecturer in Biostatistics and Health Technology Assessment, University of Bristol

NICE project team

Each technology appraisal is assigned to a team consisting of 1 or more health technology analysts (who act as technical leads for the appraisal), a technical adviser and a project manager.

Ahmed Elsada
Technical Lead

Fiona Pearce
Technical Adviser

Jeremy Powell
Project Manager

Sources of evidence considered by the Committee

The Evidence Review Group (ERG) report for this appraisal was prepared by Kleijnen Systematic Reviews:

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the 2 appraisal consultation documents. Manufacturers or sponsors were also invited to make written submissions. Professional or specialist and patient or carer groups, and other consultees, had the opportunity to give their expert views. Manufacturers or sponsors, professional or specialist and patient or carer groups, and other consultees, also have the opportunity to appeal against the final appraisal determination.

Manufacturers or sponsors:

Professional or specialist and patient or carer groups:

Other consultees:

Commentator organisations (did not provide written evidence and without the right of appeal):

The following individuals were selected from clinical specialist and patient expert nominations from the consultees and commentators. They gave their expert personal view on enzalutamide by attending the Committee meetings and providing written evidence to the Committee. They were also invited to comment on both appraisal consultation documents.

Representatives from the following manufacturer or sponsor attended the Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

ISBN 978-1-4731-0676-5